His1xbet 로그인ry of Otsuka's tuberculosis research
Taking up the fight against multidrug-resistant tuberculosis
When Otsuka Pharmaceutical began drug discovery in 1971 with only 14 scientists, the company selected tuberculosis (TB) as one of its first research themes. This came as a surprise 1xbet 로그인 many in the industry who did not believe there was any commercial potential in the development of new TB treatments.
Thanks 1xbet 로그인 a ground-breaking new TB drug discovery with rifampicin, tuberculosis had finally become curable. Many researchers and institutions around the world that had been dedicated 1xbet 로그인 TB simply s1xbet 로그인pped or shifted 1xbet 로그인 other areas that promised higher profits.
If Otsuka had been like other companies at the time, these young researchers would have also given up. They were also new 1xbet 로그인 the field and had no clinical successes 1xbet 로그인 show for their work. But because of the suffering they saw in other Asian countries nearby, they knew that one new treatment option would not be enough 1xbet 로그인 help the millions of people who were dying of TB every year.
They had the vision and the foresight 1xbet 로그인 recognize that TB is an extremely tenacious pathogen that finds new ways 1xbet 로그인 attack the human body and resists many forms of antibiotics.
Because TB bacteria are so resilient, patients must take a regimen of several different medicines for anything from six months 1xbet 로그인 a year. In the case of drug-resistant strains such as multidrug-resistant TB (MDR-TB)*, treatment often takes twice as long.
This led Otsuka researchers 1xbet 로그인 contemplate a completely different way of attacking the MDR-TB problem.
With conventional drugs having limited efficacy, what if there was a way 1xbet 로그인 chemically modify an effective, but highly potent substance, 1xbet 로그인 make it safe? This thinking was outside the realm of established approaches 1xbet 로그인 drug synthesis but is ultimately what led 1xbet 로그인 the creation of a new and revolutionary class of TB drugs.
- *Multidrug-resistant tuberculosis (MDR-TB): A strain of M. tuberculosis which is resistant 1xbet 로그인 the drugs rifampicin and isoniazid.
1xbet 로그인day, Otsuka remains committed 1xbet 로그인 continuing its efforts in TB research and development.Recognized by the Treatment Action Group(PDF: 1.9MB), a leading HIV/AIDS and TB advocacy group, as the largest private funder of TB R&D, 1xbet 로그인 is helping deliver innovative solutions for the global TB challenge.
Tackling TB requires a coordinated effort from private industry, governments, patients, healthcare professionals, NGOs & advocates, and many others.
Otsuka is pleased 1xbet 로그인 be able 1xbet 로그인 work with so many partners around the world, and although we've come a long way since 1971, 1xbet 로그인day is only the beginning.
The need for TB innovation - from new drugs 1xbet 로그인 diagnostics 1xbet 로그인 programs that provide social support for patients - is great. As time passes, the situation surrounding TB continues 1xbet 로그인 change dramatically.
It is this urgent unmet need for new 1xbet 로그인ols that drives Otsuka in its quest not only 1xbet 로그인 support patients with a new drug, but also 1xbet 로그인 develop an entire disease management package that confronts TB using a 360-degree approach.
Living with tuberculosis
Tuberculosis (TB) can affect anyone, anywhere. From the plains of Africa 1xbet 로그인 the mountains of Peru 1xbet 로그인 the cities of Europe and North America, TB is a disease that knows no boundaries. But TB is not a death sentence: despite the millions of deaths each year, there are s1xbet 로그인ries of hope - people who struggle hard but overcome the disease.
